title: Quadruple therapy with ecabet sodium, omeprazole, amoxicillin and metronidazole is effective for eradication of Helicobacter pylori after failure of first-line therapy (KDOG0201 Study).
abstract: OBJECTIVE
  An antiulcer agent, ecabet sodium, is active against Helicobacter pylori. The aim of the present study was to clinically examine whether eradication therapy, which includes ecabet sodium, is effective in eradication of H. pylori after failure of first-line therapy.
  
  
  METHODS
  Patients with peptic ulcer who failed with first-line triple eradication therapy containing clarithromycin received quadruple therapy with omeprazole (20 mg, twice daily), amoxicillin (750 mg, twice daily), metronidazole (500 mg, twice daily) and ecabet sodium (1000 mg, twice daily) for 14 days. Eradication of H. pylori was judged by 13C-urea breath test 8 weeks later.
  
  
  RESULTS
  Fifty-two patients (36 men and 16 women) were included. Their mean age was 51.4 years (range 28-73). One patient dropped out because of diarrhoea. The eradication rate was 98.0% (50/51) according to the per-protocol analysis and 96.2% (50/52) according to the intention-to-treat analysis. Side effects occurred in seven patients, but none were serious.
  
  
  CONCLUSIONS
  Quadruple therapy including ecabet sodium is useful as second-line eradication treatment for H. pylori.
authors.affiliation: Department of Gastroenterology, Kitasato University School of Medicine, Sagamihara-shi, Japan. koizumi@med.kitasato-u.ac.jp
authors.forename: W
authors.initials: W
authors.lastname: Koizumi
authors.forename: S
authors.initials: S
authors.lastname: Tanabe
authors.forename: K
authors.initials: K
authors.lastname: Nakatani
authors.forename: K
authors.initials: K
authors.lastname: Ishido
authors.forename: K
authors.initials: K
authors.lastname: Nishimura
authors.forename: M
authors.initials: M
authors.lastname: Azuma
authors.forename: T
authors.initials: T
authors.lastname: Ae
authors.forename: T
authors.initials: T
authors.lastname: Sasaki
authors.forename: K
authors.initials: K
authors.lastname: Higuchi
authors.forename: C
authors.initials: C
authors.lastname: Katada
authors.forename: N
authors.initials: N
authors.lastname: Nakayama
authors.forename: K
authors.initials: K
authors.lastname: Saigenji
mesh_terms: D045784:Abietanes / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D000328:Adult; D000368:Aged; D000658:Amoxicillin / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D000897:Anti-Ulcer Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D005260:Female; D016481:Helicobacter Infections / Q000188:drug therapy* / Q000382:microbiology; D016480:Helicobacter pylori / Q000187:drug effects* / Q000302:isolation & purification; D006801:Humans; D008297:Male; D008795:Metronidazole / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D008875:Middle Aged; D009853:Omeprazole / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D010437:Peptic Ulcer / Q000188:drug therapy / Q000382:microbiology; D010865:Pilot Projects; D016896:Treatment Outcome
chemical_list: D045784:Abietanes; D000900:Anti-Bacterial Agents; D000897:Anti-Ulcer Agents; D008795:Metronidazole; C061681:ecabet; D000658:Amoxicillin; D009853:Omeprazole